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2. ABBREVIATIONS
AGM Aorta-Gonad-Mesonephros Region
AML Acute Myeloid Leukemia 
Aml1 Acute Myeloid Leukemia 1 
Ang1 Angiopoetin1 
BM Bone Marrow
BMEC Bone Marrow Endothelial Cell 
Bmi1 B Lymphoma Mo-MLV Insertion Region 1 
BMP Bone Morphogenic Protein 
C/EBP? CCAAT/Enhancer Binding Protein 
CaR Calcium-sensing Receptor  
CFU Colony Forming Unit
ChIP-on-chip Chromatin Immunoprecipitation on chip 
c-kit Receptor for c-kit Ligand/SCF 
CLP Common Lymphoid Progenitor 
CMP Common Myeloid Progenitor 
c-Myb Myeloblastosis Oncogene 
c-Myc Myelocytomatosis Oncogene
CpG Cytosine followed by Guanine 
CSF Colony Stimulating Factor 
DC Dendritic Cell
DNA Deoxyribonucleic Acid
DNMT DNA Methyl Transferase 
E Embryonic Day
EBF Early B-cell Factor 1 
ECM Extracellular Matrix
ee Embryo Equivalent
ELP Early Lymphoid Progenitor 
Epo Erythropoietin 
Ezh2 Enhancer of Zeste Homolog 2 
FACS Fluorescence Activated Cell Sorter 
FGF Fibroblast Growth Factor 
FL Fetal Liver
Flt3 Fms-related Tyrosine Kinase 3 
Fog-1 Friend of Gata-1 
GMP Granulocyte Macrophage Progenitors 
HDAC Histone Deacetylase
HPC Hematopoietic Progenitor Cell 
HSC Hematopoietic Stem Cell 
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Ihh Indian Hedgehog 
IL Interleukin 
LacZ ?-galactosidase 
Lin Lineage 
Lmo2  LIM domain only 2 
LoxP Locus of Crossover of P1 
LSK Lineage- Sca-1+ c-kit+ cells 
LT-HSC Long-Term HSC
MBP Methyl-CpG Binding Proteins 
Mef2C Myocyte Enhancer Factor 2 C 
MEP Megakaryocyte Erythroid Progenitor 
Mll Mixed-Lineage Leukemia
MPP Multipotent Progenitor 
mRNA Messenger RNA
Ncx1 Sodium-Calcium Exchanger 1 
NK Natural Killer
OB Osteoblast 
OCL Osteoclast 
OPN Osteopontin 
Pax-5 Paired box gene 5 
p-SP Para-aortic Splanchnopleura
RNA Ribonucleic Acid
RU Repopulating Unit
Runx1 Runt-related Transcription Factor 1 
Sca-1 Stem Cell Antigen 1 
SCF Stem Cell Factor/c-kit Ligand  
Scl Stem Cell Leukemia Gene 
SDF Stromal Derived Factor 
Shh Sonic Hedgehog
SLAM Signaling Lymphocyte-Activating Molecule
SP Side Population
ST-HSC Short-Term HSC
Tal1 T-cell acute Leukemia Gene 1 
TF Transcription Factor
Tgf-? Transforming Growth Factor-beta 
Tie2 Tyrosine kinase with immunoglobulin and epidermal growth  
factor homology domains–2 
TPO Thrombopoietin 
YS Yolk Sac
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3. SUMMARY
Hematopoietic stem cells (HSCs) have the unique abilities of self-renewal and potential 
to generate all blood cell types throughout an individual’s lifetime (Weissman, 2000). In 
the adult, HSCs reside in specialized HSC microenvironments within the bone marrow. 
During fetal development, hematopoiesis occurs at multiple temporally and anatomically 
restricted sites, including the yolk sac (YS), the aorta-gonad-mesonephros region (AGM) 
and the fetal liver (FL). Due to a discrepancy in the total number of HSCs in the fetus 
before and after hematopoietic seeding of the fetal liver (E11.5-12.5) we sought to 
identify other sources for HSCs in the embryo.  
In avian embryos the allantois is a hematopoietic site and in mammals it participates 
in the formation of the placental labyrinth. Therefore, we asked whether HSCs could be 
found in the mouse placenta (Paper I). Importantly, we could show that placenta is a 
major fetal hematopoietic niche that harbors a large number of HSCs during midgestation 
(Gekas et al., 2005). Furthermore, as HSCs in placenta appear as early as in the AGM 
(E10.5), our data suggested that placenta could potentially serve as a site of de novo
generation of HSCs. However, since blood circulation is initiated already at E8.5, cells 
from other sites could theoretically migrate via the bloodstream to any other site. In order 
to address this we utilized the Runx1-LacZ knock-in and Ncx1 knockout mouse models 
(Paper II). Importantly, we could show that HSCs emerge de novo in the placental 
vasculature in the absence of circulation (Rhodes et al., 2008). Furthermore, we could 
identify defined microenvironmental niches within the placenta with distinct roles in 
hematopoiesis: the large vessels of the chorioallantoic mesenchyme serve as sites of HSC 
generation whereas the placental labyrinth is a niche supporting HSC expansion (Rhodes 
et al., 2008). Overall, these studies illustrate the importance of distinct milieus in the 
emergence and subsequent maturation of HSCs.  
 To ensure proper function of HSCs several regulatory mechanisms are in place. The 
microenvironment in which HSCs reside provides soluble factors and cell-cell 
interactions. In the cell-nucleus, these cell-extrinsic cues are interpreted in the context of 
cell-intrinsic developmental programs which are governed by transcription factors. An 
essential transcription factor for initiation of hematopoiesis is Scl/Tal1 (stem cell 
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leukemia gene/T-cell acute leukemia gene 1). Loss of Scl results in early embryonic 
death and total lack of all blood cells. Surprisingly, however, deactivation of Scl in the 
adult does not affect HSC function, but leads to impaired erythroid and platelet 
development (Mikkola et al., 2003b). In order to define the temporal window of Scl 
requirement during fetal hematopoietic development, we deactivated Scl in all 
hematopoietic lineages shortly after hematopoietic specification in the embryo (Paper 
III). Interestingly, maturation, expansion and function of fetal HSCs was unaffected, and, 
as in the adult, red blood cell and platelet differentiation was impaired (Schlaeger et al., 
2005). These findings highlight that, once specified, the hematopoietic fate is stable even 
in the absence of Scl and is maintained through mechanisms that are distinct from those 
required for the initial fate choice.
As the critical downstream targets of Scl remain unknown, we sought to identify and 
characterize target genes of Scl (Paper IV). We could identify transcription factor 
Mef2C (myocyte enhancer factor 2 C) as a novel direct target gene of Scl specifically in 
the megakaryocyte lineage which largely explains the megakaryocyte defect observed in 
Scl deficient mice. In addition, we observed an Scl-independent requirement of Mef2C in 
the B-cell compartment, as loss of Mef2C leads to accelerated B-cell aging (Gekas et al.
Submitted). Taken together, these studies identify key extracellular microenvironments 
and intracellular transcriptional regulators that dictate different stages of HSC 
development, from emergence to lineage choice to aging.  
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4. INTRODUCTION
The continuous production of blood cells, a process termed hematopoiesis, is sustained 
throughout the lifetime of an individual by a relatively small population of cells known as 
hematopoietic stem cells (HSCs). HSCs are unique cells characterized by their ability to 
self-renew and give rise to all types of mature blood cells. Given their high proliferative 
potential, HSCs need to be tightly regulated on the cellular and molecular levels or could 
otherwise turn malignant. On the other hand, the tight regulatory control of HSC function 
also translates into difficulties in culturing and expanding HSCs in vitro.  In fact, it is 
currently not possible to maintain or expand HSCs ex vivo without rapid loss of self-
renewal. Increased knowledge of the unique features of important HSC niches and of key 
transcriptional regulatory programs that govern HSC behavior is thus needed. Additional 
insight in the mechanisms of stem cell formation could enable us to recapitulate the 
processes of HSC formation and self-renewal/expansion ex vivo with the ultimate goal of 
creating an unlimited supply of HSCs from e.g. human embryonic stem cells (hESCs) or 
induced pluripotent stem cells (iPS) to be used in therapy. We thus asked: How are 
hematopoietic stem cells formed and in what cellular niches does this happen (Papers I, 
II)? What are the molecular mechanisms that govern hematopoietic stem cell 
development and differentiation (Papers III, IV)?  
- 10 -
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5. REVIEW OF THE LITERATURE
5.1. HEMATOPOIESIS
The process of hematopoiesis ensures the daily production of the over a thousand billion 
(1 x 1012) blood cells needed for the survival of an adult (Ogawa, 1993). The reason of 
this high demand is mainly due to the short life-span of neutrophils and platelets that 
need to be continuously replaced, but also that of other myeloid and lymphoid cells. To 
achieve this incredible feat, the bone marrow develops early on in life into a specialized 
niche that can support hematopoietic stem cells (see (Stier et al., 2005; Zhu and Emerson, 
2004)), which are formed during fetal development. Although HSCs are rare in numbers, 
comprising about 1 out of 105 BM cells (Harrison et al., 1988; Morrison et al., 1995), all 
blood cells originate from HSCs. In the right environment, these cells have the 
remarkable properties to give rise to all types of blood cells, termed multipotentiality,
and their ability to divide into daughter cells where either one or both remain HSCs, 
termed self-renewal capacity (Siminovitch et al., 1963). A functional requirement used to 
define true HSCs is their unique ability to long-term reconstitute the entire hematopoietic 
system of a myeloablated host (Dick et al., 1985; Lemischka et al., 1986). For this reason, 
HSCs have been under immense experimental scrutiny for the past few decades, since 
this also means that healthy HSCs can be used to treat human blood disorders. There was 
also initial promise that HSCs could change their cell-fate, through the process of 
transdifferentiation (e.g. (Krause et al., 2001; Lagasse et al., 2000; Weissman et al., 
2001), and be used to treat neurological, heart and other non-blood disorders. However, 
most such studies were shown to be either too inefficient for treatment or explained by 
processes other than transdifferentiation, such as cell-fusion, and will not be discussed 
further here (Nygren et al., 2004; Orkin and Zon, 2002; Wagers et al., 2002).  
5.2. THE HEMATOPOIETIC HIERARCHY 
Since all mature blood cells and their progenitors originate from hematopoietic stem cells, 
the HSC is on the top of the hierarchy of adult hematopoiesis. The most widely accepted 
model of hematopoiesis is depicted in Figure 1.  The most immature cells in the  
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Figure 1. The hematopoietic hierarchy. Schematic drawing of the hematopoietic tree (adapted from 
(Reya et al., 2001)), showing involved cell types and their hierarchical relationships.  
stem cell compartment are the long-term, or LT-, HSCs, named after their capacity to 
give rise to and maintain hematopoiesis for over six-eight weeks and up to lifetime after 
transplantation in mice (Dick et al., 1985; Lemischka et al., 1986). These cells have the 
most extensive self-renewal capacity, which can be assessed through serial 
transplantations. Briefly, a cell capable of extensive self-renewal will be able to 
propagate itself and its progeny also after a secondary, tertiary and so on, serial 
transplantation to new hosts (Keller and Snodgrass, 1990). The short-term (ST-) HSC is 
multipotential, but has lower self-renewal potential and thus capable only of transient 
hematopoietic reconstitution that gets lost after 6-8 weeks (Morrison and Weissman, 
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1994). The MPP, or multipotential progenitor, is a cell downstream of the LT- and ST-
HSCs that has the same multilineage differentiation capacity, but is not defined as a stem 
cell as it lacks self-renewal ability (Morrison et al., 1997b; Weissman, 2000). Up to this 
point all cells have the ability to differentiate to all mature lineages. However, the next 
differentiation step involves a lineage choice and a restriction in potential as, according to 
the commonly accepted model of hematopoiesis, either a CMP (common myeloid 
progenitor) or a CLP (common lymphoid progenitor) is formed. The CMP can give rise 
to two oligopotential cell types, the megakaryocytic/erythroid (MEP) and 
granulocyte/monocyte (GMP) progenitors, each retaining the ability to differentiate to 
platelets and red cells and granulocytes, macrophages and dendritic cells, respectively 
(Akashi et al., 1999; Akashi et al., 2000). The lymphoid branch of the hematopoietic tree 
arises at the level of the CLP, which has the potential to form B-, T-, natural killer (NK-), 
and dendritic (DC) lymphoid cells (Kondo et al., 1997). Of note, whereas all other 
differentiation steps and the formation of mature cells in the adult occur in the bone 
marrow, the differentiation and maturation of T-cells occurs in the thymus, a primary 
lymphoid organ in the chest. It should be mentioned that recent evidence point to the CLP 
as mainly a B-cell poised progenitor with no significant T-cell potential, indicating that 
the T-cell lineage branches off at a separate point during differentiation (reviewed in 
(Montecino-Rodriguez and Dorshkind, 2003)).
5.3. REGULATION OF HEMATOPOIESIS
Given the incredible repopulation potential of HSCs, in order to avoid hyper-proliferation 
or dysfunctional differentiation that could lead to blood disorders such as leukemia, it is 
evident that HSCs need to be tightly regulated (Domen and Weissman, 1999). Indeed, 
this is ensured by maintaining most of HSCs in the BM residing in the G0-, or dormant, 
phase of the cell cycle (Bradford et al., 1997; Cheshier et al., 1999). Upon the reception 
of an appropriate signal, the HSC will enter the cell cycle and either divide symmetrically,
giving rise to two daughter cells both being either HSCs, or asymmetrically, giving rise to 
a progenitor, which will subsequently divide and differentiate into mature cells, and to an 
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HSC, thus retaining the numbers of HSCs (Morrison et al., 1997a). In steady-state
hematopoiesis asymmetric cell division is most common, whereas during hematopoietic
stress, such as during the repopulation of a host, most HSCs will divide symmetrically to 
initially expand their own numbers before prioritizing asymmetrical divisions (Osawa et 
al., 1996). In certain disease states, such as bone marrow failure, HSCs divide 
symmetrically in a non-self-renewal manner, thus progressively diminishing in numbers 
and eventually becoming extinct. Fate decisions of HSCs are the outcome of the interplay 
between cell-extrinsic and cell-intrinsic signals and will be discussed more next.  
5.3.1. CELL-EXTRINSIC REGULATORY MECHANISMS
5.3.1.1. THE HEMATOPOIETIC MICROENVIRONMENT
As can be appreciated, the factors regulating the above mentioned processes of stem cell 
proliferation, self-renewal and differentiation, are more complex than can be included in 
this text and not fully known. However, several key notions could be worth discussing.
The concept that the nature of the physical residence of cells is important is implied 
by the Greek term anoikis – homelessness – which is used to describe cell death in the 
absence of appropriate cell-extracellular matrix interactions. In recent years, it has 
become clear that probably the single most important factor that governs also 
hematopoietic stem cell behavior is the characteristics of the microenvironment, or niche,
in which the HSC resides (Adams and Scadden, 2006; Suda et al., 2005). It is an 
unfortunate fact that removing HSCs from their in vivo places of residence causes rapid 
loss of self-renewal capacity and subsequent terminal differentiation.  
Although mostly undefined, the hematopoietic niche in the bone marrow has been 
shown to be comprised of several key cellular and molecular components (Zhu and 
Emerson, 2004). Notably, the osteoblast (OB), a non-hematopoietic bone-forming cell, 
was shown to be directly implicated in positively regulating HSC numbers (Calvi et al., 
2003). Osteoblasts line the endosteal surface of trabecular bone, a region within the bone 
marrow which was known to be preferentially inhabited by immature hematopoietic cells,  
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Figure 2. The bone marrow hematopoietic stem cell niche. Schematic drawing of the HSC 
microenvironment within the bone marrow comprised of the osteoblastic and vascular niches. The key 
cellular components of the niche are osteoblasts (OB), which express several ligands important for HSC 
function, and osteoclasts (OCL) whose bone resorbing activity has been implicated in HSC engraftment 
through signaling of the calcium receptor. The vascular niche, although less defined, is comprised of bone 
marrow endothelial cells (BMEC), and has been shown to regulate HSC maintenance and platelet (PLT) 
development through expression of SDF-1 and FGF4. mbSCF: membrane bound SCF, CaR: Calcium-
Sensing Receptor. 
whereas more differentiated hematopoietic cells are located in the BM cavity further 
away from the endosteum (See Figure 2) (Taichman and Emerson, 1998). Among the key 
signaling components proposed for osteoblast-HSC interaction are adhesion molecules 
N-cadherin, which upon activation releases ?-catenin, a potent signaling molecule of the 
wnt-pathway, and Notch1 receptors on HSCs that interact with Jagged1 ligands on OBs 
to signal through Notch activation pathways. An interesting finding, implicating the role 
of cytokines in HSC-niche interactions, is the preferential adhesion of HSCs on 
osteoblastic regions that express membrane bound SCF (Driessen et al., 2003; Taichman 
and Emerson, 1998). Osteoclasts (OCLs), specialized bone-resorbing macrophage-like 
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cells of hematopoietic descent, were recently implicated as an additional cellular 
component of the endosteal HSC niche. Notably, induction of osteoclastogenesis by 
RANK-ligand (RANKL), a member of the tumor necrosis factor (TNF) family of 
cytokines and normally produced by OBs, led to mobilization of HSCs and progenitors 
away from the BM (Kollet et al., 2006). The proposed mechanism of RANKL-induced 
HSC mobilization includes upregulation of protease MMP-9 and cathepsin K on OCLs 
which cleave membrane-bound SCF on OBs, as well as reduction in production of 
osteopontin, which regulates HSC numbers (Nilsson et al., 2005; Stier et al., 2005). In 
addition, it was shown that loss of Calcium-sensing Receptor (CaR) on HSCs resulted in 
a defect in HSC homing to the endosteal niche, which correlated with diminished binding 
to collagen type 1 (Adams et al., 2006). This suggests that the calcium gradient within the 
remodeling bone, a direct outcome of OCL activity, is important for engraftment of HSCs 
into the endosteal niche. Worth mentioning is the osteopetrotic op/op mouse model, 
which due to lack of functional macrophage-colony stimulating factor-1 (M-CSF) leads 
to severe deficiencies of macrophages and OCLs resulting in excessive bone formation. 
These mice exhibit occlusion of the marrow cavity and reduced hematopoietic activity 
(Nilsson and Bertoncello, 1994). However, a stromal cell line isolated from op/op bone 
marrow, termed OP9, displays remarkable hematopoietic-promoting potential and has 
been widely used by us and others as an invaluable tool for in vitro culture of HSCs and 
progenitors (see Papers II, IV and (Carlyle et al., 1997; Kodama et al., 1994)).  
In addition to the osteoblastic niche found exclusively in the adult bone marrow, there 
exist specialized vascular HSC niches within bone marrow and other adult tissues, such 
as the spleen and liver, which are known sites of extramedullary hematopoiesis (reviewed 
in (Zhang and Li, 2008)). The vascular niche in the BM is even less defined than the 
osteoblastic niche, but its functional components appear to include reticular cells, which 
express high levels of the chemokine SDF-1, important for HSC maintenance (Sugiyama 
et al., 2006). In addition, hematopoietic cell interactions with vascular endothelium are 
likely to be vital as exemplified by studies showing association of a large population of 
HSCs with sinusoidal endothelium in multiple organs, and the role of BM endothelial 
cells (BMECs) in sinusoidal spaces in promoting megakaryopoiesis and platelet 
production through SDF-1 and FGF-4 (See Figure 2) (Avecilla et al., 2004; Kiel et al., 
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2005). Importantly, as HSCs are formed during fetal development prior to bone formation, 
fetal hematopoietic niches are exclusively vascular niches. From the perspective of this 
thesis, the variety of the distinct microenvironmental niches provided by fetal tissues 
during the initial stages of hematopoiesis is likely to contain important clues as to the 
signals required for HSC emergence, maturation and expansion and would have major 
clinical applications for de novo generation of HSCs. Fetal hematopoietic niches will be 
discussed in more detail later.
5.3.1.2. HEMATOPOIETIC CYTOKINE SIGNALING
In addition to the above mentioned extrinsic cues regulating hematopoietic stem cells, 
the HSC niche and other cell types secrete soluble regulatory factors. One class of 
regulators that has been shown to affect hematopoietic decisions throughout the blood 
hierarchy is the hematopoietic cytokine family (Metcalf, 1998). Cytokines are 
extracellular molecules that exert their function through interaction with cell membrane-
bound cytokine receptors which send their message to the cell nucleus where it is 
interpreted to yield a cellular response. One of the important receptor regulating 
hematopoiesis is c-kit, a member of the platelet-derived growth factor receptor (PDGFR) 
group, belonging to the protein receptor tyrosine kinase (RTK) family of genes (Chabot 
et al., 1988; Geissler et al., 1988; Matthews et al., 1991; Rosnet et al., 1991a; Rosnet et 
al., 1991b). The common feature of the genes in this group is that they encode for 
proteins that span the cellular membranes. The extracellular domain acts as a receptor for 
the corresponding ligand, and the intracellular portion consists of regions with inducible 
enzymatic activity capable of phosphorylation of tyrosine residues on specific target 
amino-acid sequences. Thus, an extracellular signal can be propagated to the interior of 
the cell upon ligand binding and subsequent phosphorylation and activation of the 
receptor. This means that only cells expressing the receptor will understand the cytokine 
message. Indeed, whereas the ligand of c-kit, stem cell factor (SCF), is widely expressed 
in many tissues, the expression of the receptor is much more limited to specific cellular 
subsets of the body (reviewed in (Lyman and Jacobsen, 1998)). This fact has not only 
facilitated the identification of the cells where each ligand confers its biological activity, 
but also provided for a tool to functionally dissect different subsets of cells based on the 
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relative or absolute levels of receptor expression. In fact, expression of c-kit was found to 
be predominantly restricted to immature progenitor/stem cell subsets (Metcalf and Nicola, 
1991; Rasko et al., 1995). Notably, c-kit is expressed on LT- and ST-HSCs, where SCF 
has been shown to be a critical regulator controlling their proliferation and differentiation, 
as naturally occurring and engineered mutations and deletions of c-kit seriously affects 
hematopoiesis and stem cell function (Ogawa et al., 1991; Ogawa et al., 1993; Okada et 
al., 1991; Russell, 1979; Silvers, 1979). 
Other cytokines worth mentioning in this regard are the members of hematopoietin 
family, which include receptors for interleukins (IL), erythropoietin (EPO), 
thrombopoietin (TPO) and colony stimulating factors (e.g. granulocyte-macrophage 
colony stimulating factor; GM-CSF). A couple of these deserve a brief introduction as 
they have been used as growth factors for in vitro culture assays in the studies presented 
herein. Firstly, interleukins 3 (IL3) and 6 (IL6) are widely used for in vitro cultures of 
hematopoietic stem and progenitor cells, as they play important roles in cell growth and 
support a variety of myelo-erythroid differentiation pathways. Supplementing 
myeloerythroid cultures with TPO and IL11 promotes megakaryocytic development and 
platelet release, whereas G-, M- or GM-CSF drives differentiation towards the 
granulocyte and macrophage  lineages. It is worth noting that the receptor of TPO, c-mpl, 
acts both as a late-acting factor to stimulate megakaryocyte and platelet formation, and is 
expressed on immature stem and progenitor cells. Concordantly, loss of TPO or c-mpl 
leads to a deficiency in megakaryopoiesis as well as hematopoietic stem cell numbers 
(Kimura 1998). The importance of growth factor EPO in erythropoiesis is made evident 
by the EPO and EPO-receptor knockout mice, which are embryonic lethal and display 
severe anemia (Lin et al., 1996). Interleukin 7 (IL7) has been shown to play a non-
redundant and key role in lymphocyte development (Peschon et al., 1994; von Freeden-
Jeffry et al., 1995). Specifically, mice lacking either IL7 or its receptor, IL7R?, display a 
profound reduction of both thymic and peripheral thymocyte numbers and a near 
complete absence of B-cell progenitors in the adult (Peschon et al., 1994; von Freeden-
Jeffry et al., 1995). IL7 is thus widely used as a promoter of B- and T-cell differentiation 
in vitro.
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Finally, an important notion of cytokine signaling is cytokine synergy, as many 
cytokine signaling pathways have redundant and additive functions. As an example, 
PDGFR family member flt-3 has been shown to synergize with IL7R? in regulating 
lymphoid development. Flt3 is expressed on early lymphoid progenitors (ELPs), common 
lymphoid progenitors (CLPs) and early B- and T-cell progenitors (Igarashi et al., 2002; 
Rasko et al., 1995; Sitnicka et al., 2002). Mice deficient in flt3 or its ligand (flt3-L), have 
near normal levels of mature B-cells and T-cells, but have largely reduced early B- and 
T-cell progenitors (McKenna et al., 2000; Sitnicka et al., 2002). However, mice deficient 
in both flt3-ligand and IL7R? exhibit a complete block of all stages of adult and fetal B-
cell development as well as extensive reductions in fetal and postnatal thymic progenitors 
that result in a loss of active thymopoiesis in adult mice (Sitnicka et al., 2003; Sitnicka et 
al., 2007). Thus, the combined phenotype of loss of flt3 and IL7R signaling is more 
drastic than the phenotypes of either one, revealing synergy between these signaling 
pathways.
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5.3.2. CELL-INTRINSIC REGULATORY MECHANISMS
Having briefly outlined some important cell-extrinsic regulatory mechanisms mediated 
through cell-niche interactions and soluble factors such as cytokines we are now ready to 
enter the hematopoietic cell nucleus and discuss the cell-intrinsic fate decision machinery. 
For the purposes of this text, this section will be broadly divided into the functions of key 
hematopoietic transcription factors and a brief introduction to epigenetic regulation of 
transcription. Not discussed in detail are regulators of cell-cycle and apoptosis 
(programmed cell-death), which despite their important roles in HSC homeostasis fall 
largely outside of the scope of this thesis (Kondo et al., 2003; Teitell and Mikkola, 2006).
5.3.2.1. TRANSCRIPTIONAL REGULATION OF HSCS
Gene regulatory programs are governed by transcription factors (TFs), which are proteins 
with sequence-specific DNA-binding activity that recruit co-factors and/or other TFs and 
initiate transcription of specific genes. Of note, TF recruitment of histone 
acetyltransferases (HATs) or histone deacetylases (HDACs) is associated with 
transcriptional activation or repression, respectively, though processes described below.  
Not surprisingly, TFs play a major role in all stages of hematopoiesis, from commitment 
to the hematopoietic lineage, to emergence and maturation of HSCs and finally lineage 
choice (Orkin, 2000; Sieweke and Graf, 1998; Teitell and Mikkola, 2006). As suggested 
previously, transcriptional dysregulation of hematopoiesis often leads to leukemia, 
indicating not only the potency but also the fine balance between a physiological or 
pathological action of a certain transcription factor. In fact, many genes determined as 
essential regulatory factors in hematopoiesis were first identified from chromosomal 
translocations or as being misexpressed in human leukemias.  
One such transcription factor, as implied by its name, is stem cell leukemia/T-cell 
acute leukemia 1 (Scl/Tal1) whose aberrant activation is found in over 60% of childhood 
and adult T-ALL cases (Bash et al., 1995). Scl is a member of the basic helix-loop-helix 
(bHLH) family of transcription factors, is known to heterodimerize with other bHLH 
factors including E12 and E47, and in hematopoietic cells is part of a large transcriptional 
complex that includes Gata-1 and LIM-only proteins Lmo2 and Ldb-1 (Hsu et al., 1991; 
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Wadman et al., 1997; Voronova and Lee, 1994). The genetic deactivation, or knockout, 
of Scl in mice leads to a total lack of blood cell formation in the embryo, and vascular 
and cardiac defects that together lead to embryonic death at embryonic day (E) 9.5 
(Shivdasani et al., 1995; Visvader et al., 1998). Hence, it is evident that Scl is essential 
for establishment of hematopoiesis and therefore was postulated to be required also for 
proper HSC function. However, deactivation of Scl in the adult, using the Cre/LoxP 
recombination system which enables tissue- and/or time specific conditional deactivation 
of genes, showed that, surprisingly, Scl is dispensable for adult HSC function (Mikkola et 
al., 2003b). On the other hand, a requirement of Scl in erythroid and megakaryocyte 
differentiation was revealed, as inducible deactivation of Scl in adult mice leads to severe 
anemia and thrombocytopenia (Mikkola et al., 2003b). These data suggest distinct roles 
of Scl during different developmental stages and in different cellular contexts.
Ezh2
Bmi1
Hlf
Aml1 Ebf
Stat5 
Scl 
Lmo2
Pu.1 Aml1
Mll Pu.1 Gata-2
Fog-1
Fog-1
Scl 
Figure 3. Transcription factors regulating HSC fate and lineage commitment. The picture shows TFs 
crucial for fetal hematopoiesis and either positively (+) or negatively (-) regulate adult HSC self-renewal. 
Furthermore, TFs important for different stages in the hematopoietic development are shown throughout 
the hierarchy.
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In particular, Scl is critical for HSC generation in the fetus but not required for HSC 
maintenance in the adult. The requirements of Scl during HSC development and efforts to 
identify its target genes will be discussed in greater detail below (Papers III and IV). 
Other transcription factors important for fetal hematopoiesis include Lmo2, Gata-2, 
Aml1/Runx1, and Mll (see Figure 3). Mice deficient in Lmo2, a binding partner of Scl, 
display largely similar defects in primitive and definitive hematopoiesis as Scl (Yamada 
et al., 1998). Loss of Gata-2 leads to proliferation defects of nascent HSCs, whereas loss 
of mixed leukemia factor (Mll) has no effect on primitive hematopoiesis or the 
emergence of definitive hematopoietic cells, but rather leads to loss of HSCs (Ernst et al., 
2004; Tsai et al., 1994). A transcription factor displaying an intermediate phenotype is 
Runx1/Aml1, which has been shown to be essential for the development of all definitive 
but not primitive hematopoietic cells during ontogeny (North et al., 1999; Okuda et al., 
1996). Interestingly, as Runx1 is specifically and continuously expressed in 
hematopoietic stem and progenitor cells, a mouse model where LacZ is knocked in to the 
runx1-locus (Runx1-LacZ) was engineered (North et al., 2002) and is a valuable tool for 
the localization of emerging hematopoietic cells during ontogeny, as we shall see in 
Paper II.
Once the hematopoietic system is established, transcription factors play a crucial role 
in lineage specification, as demonstrated by gain- or loss of function studies (Orkin, 
2000). For our purposes, some key concepts will be briefly introduced. Firstly, 
transcription factors can be intuitively regarded as ‘master regulators’ that govern lineage 
programs. Such a transcription factor would have to be able to enforce its lineage 
program on cells of a different lineage. Notably, Gata-1, a TF essential for the 
development of both primitive and definitive erythropoiesis and megakaryopoiesis was 
shown to reprogram CLPs into progenitors with erythropoietic and megakaryopoietic 
potential (Fujiwara et al., 1996; Iwasaki et al., 2003; Pevny et al., 1995; Pevny et al., 
1991). Secondly, the actual concentration of a TF has been shown to influence lineage 
choice, as exemplified by Pu.1, a TF important for myeloid maturation, whose high 
expression leads to macrophage differentiation whereas low expression leads to B-cell 
differentiation (DeKoter and Singh, 2000). It is likely that Pu.1 negatively regulates key 
- 22 -
Hematopoietic Stem Cell Development and Transcriptional Regulation 
B-cell factors, and illustrates the concept of lineage antagonism: for a specific lineage 
program to be turned on others have to be shut down. Indeed, Pu.1 was shown to 
physically interact with and repress transactivation of key transcription factor Pax5, 
which is crucial for B-cell development (Nutt et al., 1999). Given the fact that HSCs are 
multipotential, step-wise lineage commitment is in fact as much a question of lineage 
restriction as lineage choice.
Lastly, the DNA itself or proteins associated with it act as an additional 
transcriptional regulatory entity, which is comprised of several layers of regulatory 
elements loosely termed ‘epigenetics’, and will be discussed next. 
5.3.2.2.EPIGENETICS
Historically, the meaning of the term epigenetics has had both currently misleading and 
confusing meanings, from “how genotypes give rise to phenotypes during development” 
to “heritable changes in gene function that cannot be explained by changes in DNA 
sequence” (Russo et al., 1996; Waddington, 1957). By definition, both terms are correct, 
as the Greek prefix epi- implies features that are ‘on top of’ or ‘in addition to’ genetics. 
For the sake of specificity, the term epigenetics will here be used to describe three aspects 
of chromatin organization: DNA methylation, genomic imprinting and histone 
modifications (Kouzarides, 2007). In recent years, the importance of epigenetic 
modifications for cell identity, cellular memory and fate choice has been made evident; 
however, currently very little is known about these processes.
The first of the epigenetic marks to be discovered was DNA methylation, which 
involves methylation of cytosine bases by DNA methyltransferases (DNMTs) within 
gene promoter regions (Methyl-CpG) and is associated with a repressed chromatin state 
and inhibition of gene expression (reviewed in (Klose and Bird, 2006)). It has been 
shown that a class of proteins (methyl-CpG-binding proteins, MBPs) that recognize and 
bind methyl-CpG can recruit transcriptional co-repressors, such as HDACs, as well as 
modify surrounding chromatin, thereby silencing transcription (Boyes and Bird, 1991; 
Jones et al., 1998). Thus, the level of promoter methylation, as can be assessed through 
bisulphite sequencing, can be used to predict availability of the promoter and 
transcriptional potential of a certain gene.    
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DNA is at any given moment, except during mitosis or meiosis, organized into units 
of nucleosomes which are each composed by a globular octamer of four core histones 
(H3, H4, H2A and H2B). It was shown that most amino-acids on the N-terminal tails of 
histones carry a vast variety and number of post-translational modifications, including 
acetylation, methylation and phosphorylation and are important epigenetic regulators 
(reviewed in (Kouzarides, 2007). Functionally, histone modifications act either on a 
global chromatin level to establish zones of DNA accessibility (euchromatin) or 
inaccessibility/protection (heterochromatin), or on DNA-based processes such as 
transcription of individual genes. Briefly, acetylation of specific lysines (e.g. H3K9Ac) 
correlates with transcriptional activation, whereas lysine methylation can be either 
activating (e.g. H3K4me) or repressing (e.g. H3K9me) depending on the lysine. 
Interestingly, a recent study shows that the differential expression of dimethylation or 
trimethylation on Histone 3 Lysine 4 (H3K4me2+/H3K4me3-) on lineage-specific 
promoters marks developmentally ‘poised’ genes, i.e. genes that are currently silenced 
but have the potential to become expressed (Orford et al., 2008). On the other hand, 
genes displaying both marks (me2+/me3+) are transcriptionally active (Orford et al., 
2008). As such, a so-called “histone-code” emerges that together with DNA methylation 
patterns contributes to environmentally responsive gene expression programs.  
Most of the knowledge of epigenetic modifications comes from studies in lower 
eukaryotes, such as the budding yeast. Importantly, also in vertebrate biology and within 
the hematopoietic system, HSC function has been shown to be linked to epigenetic 
modifications (Teitell and Mikkola, 2006). For example, the polycomb-group protein 
Ezh2 regulates HSC self-renewal capacity and was shown to bind DNMTs, thus 
controlling gene silencing (Vire et al., 2006). Also transcription factor Pu.1 mentioned 
above, and oncogene c-myc, an essential proliferation factor and inducer of apoptosis, 
have the ability to associate with DNMTs and direct gene repression at specific loci 
(Brenner et al., 2005; Kihara-Negishi et al., 2001). A further elucidation of both global 
and site-specific epigenetic marks will undoubtedly become a valuable tool in 
developmental hematopoiesis, as progenitors poised towards certain lineages, or 
emerging HSCs could be identified as they become specified. A valuable tool for site-
specific epigenetic mark analysis that deserves mention is the ChIP-on-chip technique 
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(Buck and Lieb, 2004). Briefly, as the name implies, it combines traditional chromatin 
immunoprecipitation (ChIP) techniques with modern microarray technology and can be 
used for genome-wide analysis of TF-to-DNA binding. In its simplest form it can reveal 
whether, and on what gene promoters, a certain transcription factor binds in any given 
cellular context. In combination with interrogation of specific epigenetic marks using 
antibodies to modified histones, this technique is very informative as it tells not only if a 
transcription factor binds to a gene, but also whether the gene itself is activated or 
repressed (see Paper IV).
5.3.3. HEMATOPOIETIC FATE DETERMINATION
In summary, HSC fate decisions, such as quiescence, self-renewal and differentiation, are 
the outcome of a tightly orchestrated interplay between cell-extrinsic cues such as 
cytokine signalling and cell-cell interactions imparted from the niche, and cell-intrinsic 
regulatory programs in the nucleus governed by transcription factors that act in the 
context of epigenetic modifications. How the interpretation process in stem cells works is 
still not fully understood, but two models have been proposed (Enver et al., 1998; 
Metcalf, 1998). The first model suggests that lineage choice has already been decided 
intrinsically by chance (Enver et al., 1998). The role of the external cues imparted by the 
niche in this model would be to regulate the survival and expansion of a cell that is 
responsive for the cytokine message, while having no effect on a cell of a non-compatible 
fate, thus selecting for the responsive cell subset over the other. This model, due to the 
effect of chance in cell fate decision, is called the stochastic or permissive model.  
On the other hand, a model that ascribes a more direct role of cell-extrinsic factors in 
the regulation of cellular decisions is the instructive model. In this model, transcriptional 
regulatory programs are induced as a result of external signaling (Metcalf, 1998). Hence, 
the stem or progenitor cells would be waiting for the appropriate extrinsic signals to 
stimulate or inhibit different cellular programs, such as to differentiate to certain lineages, 
undergo self-renewal etc. As experimental support exists for both models (e.g. (Fairbairn 
et al., 1993; Kondo et al., 2000)) they could both be correct, operating at different levels 
of hematopoiesis or even simultaneously. Theoretically, a stochastic decision could be 
reversed or nullified by an instructive signal, or due to a stochastic over-advantage, an 
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instructive signal is rendered insufficient. Pertaining to this thesis is the conundrum that 
the same transcription factor can direct a cell towards distinct fate outputs in different 
cellular systems (addressed in Papers III, IV). The advent of epigenetic research will 
add to our understanding of these processes and will allow not only a more accurate 
prediction of cell-fate determination but will likely open up for engineering the 
epigenome towards specific lineage or ‘stemness’ programs of choice. 
5.4. FETAL HEMATOPOIETIC DEVELOPMENT
As mentioned earlier, in the adult HSCs reside primarily in the bone marrow. However, 
during fetal development, when the hematopoietic program is initiated and the first HSCs 
are formed, hematopoiesis occurs at multiple temporally and anatomically restricted sites 
(Mikkola and Orkin, 2006). These sites likely impart unique cues critical for the proper 
development of the emerging hematopoietic cells.  The first step towards the initiation of 
hematopoiesis is the specification of a subset of cells belonging to the mesodermal germ 
layer, termed hemangioblast cells for their potential to give rise to both blood and 
endothelial cells (Choi et al., 1998; Huber et al., 2004; Robertson et al., 2000; Sabin, 
1920). This process depends critically on a number of genes, such as Scl as mentioned 
above (Porcher et al., 1996; Shivdasani et al., 1995). 
In the mouse, the first hemangioblasts arise in the primitive streak of the embryo and 
migrate to the yolk sac as early as embryonic day (E) 7.0-7.5 to form so called blood
islands (Palis et al., 1999). Thus the yolk sac becomes the first site where blood is formed. 
However, this so called primitive hematopoiesis differs from adult-type, or definitive
hematopoiesis in several ways. First of all, the erythrocytes being formed at this stage are 
nucleated, and express embryonic globins. Secondly, only these primitive erythrocytes 
and a small fraction of early macrophages are formed, compared to the many blood 
lineages in the adult (Palis et al., 1999). Finally, and importantly, the primitive wave of 
hematopoiesis occurs independently of HSCs, as indicated by the fact that loss of Runx1 
or Mll leads to loss of definitive but not primitive hematopoiesis, as mentioned above. In 
fact, it is not until three days later at E10.5 that the first definitive HSCs can be found, as 
assessed by transplantation experiments. The main site where de novo generation of the 
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first HSCs occurs is called the aorta-gonad-mesonephros region (AGM) where rare HSCs 
bud out from so called hemogenic endothelium and into the vessel lumen (Cumano et al., 
1996; de Bruijn et al., 2000; Godin et al., 1999; Medvinsky and Dzierzak, 1996; Muller et 
al., 1994). Alternatively, these nascent HSCs could theoretically arise in the stroma below 
the endothelial lining and transverse into the lumen of the aorta. However, currently the 
hemogenic endothelium theory is the most favored one. Interestingly, the newly formed 
HSCs cannot be retained in the AGM and instead migrate to the fetal liver, (FL), which 
they seed starting at E11 – E11.5 (Kumaravelu et al., 2002). In the fetal liver, HSCs are 
able to expand exponentially and also undergo differentiation into multiple lineages, and 
thus the fetal liver serves as the main hematopoietic site until shortly before birth when 
hematopoiesis shifts to the bone marrow (Ema and Nakauchi, 2000). It is important to 
note that despite of the great capacity of the fetal liver niche to expand and differentiate 
HSCs, no de novo formation of HSCs takes place there. Thus, as previously hinted, HSCs 
and definitive progenitors from the AGM have been assumed to be responsible for the 
colonization of FL (Houssaint, 1981; Johnson and Moore, 1975). However, the 
exceptional increase of HSC numbers between E11.5 – E12.5 taken together with the 
length of the cell cycle, have raised the question whether also immature HSC precursors 
from the yolk sac, or yet another, unknown, site could possibly contribute to establishing 
the fetal liver HSC pool (Kumaravelu et al., 2002).  
In the avian system there is an additional mesodermal appendage that is active in 
hematopoiesis, namely the allantois, which was shown to contain hemangioblasts and 
where de novo hematopoiesis occurs (Caprioli et al., 1998; Caprioli et al., 2001). In mice, 
the allantois, which develops from the epiblast, grows out as an extension of the posterior 
primitive streak into the exocoelomic cavity to fuse at E8-8.5 with the chorion, thus 
forming the chorio-allantoic portion of the placenta (Adamson et al., 2002; Downs, 2002; 
Downs and Gardner, 1995; Rossant and Cross, 2001). As mentioned, the allantois has a 
high vascular potential and, indeed, the fusion product soon gives rise to a complex 
vascular network of endothelial cell-lined vessels called the placental labyrinth. This 
vascular compartment allows for the exchange of gases and nutrients between the 
trophoblast-lined maternal blood spaces and the fetal blood system, thus ensuring 
survival for the fetus (Adamson et al., 2002).  
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In addition to these well established roles of the placenta there were preliminary 
findings reporting hematopoietic potential in the placenta (Till and McCulloch, 1961) 
(Melchers, 1979). These initial studies were not followed up until our collaborators 
assessed hematopoietic potential in the placenta by in vitro cultures (Alvarez-Silva et al., 
2003). However, since hematopoietic progenitors arise prior to and independently from 
the genesis of definitive HSCs, it was important to define whether the placenta supports 
the development of definitive HSCs (see Paper I), and whether hematopoietic cells in the 
placenta are generated there de novo (Paper II).
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6. AIMS OF THE PRESENT STUDY
The general questions that inspired this study were: How are hematopoietic stem cells 
formed and in what cellular niches does this happen? What are the gene transcriptional 
mechanisms that govern stem cell development and differentiation?  
6.1. SPECIFIC AIMS
To address these questions the specific aims of my thesis are:  
1) To investigate whether the placenta is a hematopoietic organ (I) 
2) To investigate whether HSCs in the placenta are generated de novo and, if so, in
what microenvironmental niches HSC generation and maturation occurs. (II) 
3) To define the temporal window of Scl requirement for HSC formation (III) 
4) To identify and characterize target genes of Scl in hematopoiesis (IV) 
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7. MATERIALS AND METHODS
A summary of the methods used in the work presented in this thesis can be found in 
Table 1. The details of each method are presented in the original publications. 
Methods Used Papers
Dissection of fetal hematopoietic and other organs I-IV
Preparation of single-cell suspension of organs for further 
analysis 
I-IV
In vitro stroma-free (methylcellulose cultures) for assessment of 
hematopoietic clonogenic potential
I-IV
In vitro stroma co-culture (on OP9-GFP, OP9-DL1 assays for 
assessment of hematopoietic potential
II-IV
In vivo transplantation assays for assessment of HSC activity and 
numbers I, III, IV
Multi-color flow-cytometry (FACS) for phenotypical 
identification of hematopoietic and other populations I-IV
Multi-color FACS cell sorting for functional assessment of 
hematopoietic populations
I-II, IV
Immunohistochemical analysis of tissues II
Microarray (Affymetrix) analysis for genome-wide gene 
identification IV
PCR and real-time Q-PCR for analysis of gene expression I-IV
Complete blood count (CBC) test for blood composition analysis IV
Chromatin immunoprecipitation on chip (ChIP on chip) for 
genome-wide identification of protein to DNA binding
IV
Table 1. Outline of methods used in the work presented in this thesis.  
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8. RESULTS AND DISCUSSION
8.1. PLACENTA IS A NOVEL HEMATOPOIETIC ORGAN THAT HARBORS A 
LARGE POOL OF HSCS DURING MIDGESTATION (I)
Hematopoietic stem cells emerge during fetal development in temporally and 
anatomically restricted sites. Although the placenta was not generally considered as a 
hematopoietic organ, a study by the group of Dieterlen-Liévre suggested the presence of 
hematopoietic progenitors in midgestation placenta (Alvarez-Silva et al., 2003). Thus, the 
aim of this study was to investigate the possible involvement of the placenta in the 
genesis, expansion and/or differentiation of hematopoietic stem cells during fetal 
development. 
 In order to accomplish this, we performed a spatial and temporal analysis of HSC 
activity, using the limiting dilution long-term competitive repopulation assay (Harrison, 
1980; Jones et al., 1996), the most reliable and stringent assay for detection and 
quantification of HSCs. Briefly, hematopoietic tissues including the placenta, fetal liver, 
yolk sac, the AGM, fetal blood and others, from E10.5 – E18.5 mouse embryos were 
dissected. Single-cell suspensions were performed by treatment with collagenase. 
Clonogenic progenitors were assayed on in vitro methylcellulose colony forming assays, 
and hematopoietic stem cell activity was assessed by transplantation of limiting dilutions 
of fetal tissue samples into lethally irradiated recipients. The use of the congenic CD45 
model allowed us to distinguish between fetal and maternal cells, as well as support, 
endogenous and donor cells in the transplantation setup. Blood from transplanted mice 
was analyzed for multilineage reconstitution by multi-color FACS at 4 – 6, 10 – 12 weeks 
and 5 – 12 months, and serial transplantations of primary recipient BM was performed at 
10 – 12 weeks or 5 – 8 months; secondary recipients were analyzed the same way.  
It has been shown that the first cells capable of reconstituting adult hematopoiesis are 
found in the AGM region as early as E10.5 – E11.0, albeit at very low levels 
(Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996; Muller et al., 1994). 
Interestingly, we could detect rare (0.1 RUs/ee; repopulating units/embryo equivalent) 
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transplantable hematopoietic cells in the placenta already at E10.5, or 33-36 somite pairs 
(sp), as well as in the caudal half of the embryo, which includes the P-Sp, and in the yolk 
sac, but never in the rostral half of the embryo, decidua or blood. However, 
hematopoietic reconstitution at this stage was very low (>1 – 5%) and often transient, 
even upon transplantation of 3ee of each tissue, indicating the rarity and/or immaturity of 
these cells throughout the conceptus. In support of the latter, it has been shown that cells 
incapable of hematopoietic reconstitution of normal adult mice, could still possess robust 
hematopoietic potential when transplanted into lymphoid deficient, e.g. Rag2-/- ?c-/-
(Cumano et al., 2001), or newborn (Yoder et al., 1996) mice. These studies suggest that 
certain maturation events, such as upregulation of MHC class I antigens (Cumano et al., 
2001), need to occur in order for these cells to engraft and survive in an adult wild-type 
host.
At E11.0 (37-40 sp) the first cells capable of sustained multilineage high-level 
(>10%) reconstitution were found in the AGM as well as in the placenta, which contained 
roughly half of all long-term repopulating units (LT-RUs) in the embryo. Importantly, 
although the circulating blood and fetal liver rudiment contained abundant clonogenic 
progenitors, no HSCs were present in circulation or fetal liver until 12 hours later, at 
E11.5 (41-45 sp), consistent with other reports (Kumaravelu et al., 2002). During this 
period of time, both numbers and reconstitution levels increased for HSCs in all 
hematopoietic sites except in the blood where no >1% reconstitution was noted. Taken 
together, these data show that onset of HSC activity during fetal development occurs not 
only in the AGM and yolk sac, as previously thought, but also coincides in the placenta. 
Importantly, HSC activity in the placenta precedes the appearance of HSCs in the fetal 
liver and circulation.
In spite of the similar temporal onset and level of hematopoietic activity in the AGM 
and the placenta, the placenta HSC pool was found to expand drastically after E11.5 to 
contain ~50 LT-RUs by E12.5, in striking contrast to the AGM and yolk sac which 
increased from ~2 to 3 RUs during the same 24-hour period (Figure 4A). The placental 
HSC expansion is similar in magnitude to that in the fetal liver (~25x and ~30x, 
respectively), which by E12.5 was found to contain ~100 RUs/ee. Importantly, in contrast 
to the fetal liver where HSC expansion was paralleled with a major (~100x) expansion 
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Figure 4. Developmental Kinetics and Phenotype of Placental HSCs and Clonogenic Progenitors. (A) 
Number of total LT-RUs in fetal hematopoietic sites representing ability to repopulate peripheral blood 
>10–12 weeks after transplantation. (B-C) Surface phenotype analysis of placental and fetal liver HSCs and 
progenitors by flow cytometry for expression of CD34 and c-kit. (D-E) Distribution of (D) HSCs and (E) 
clonogenic progenitors between the four isolated populations indicated in (B) and (C) (n = 3 experiments). 
The numbers in (D) indicate the number of engrafted mice/total recipients transplanted with 0.05–0.3 ee 
from each population. 
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of clonogenic progenitors, only a very modest (~2x) expansion of progenitors took place 
in the placenta. These results show not only that the placenta, in contrast to the yolk sac 
and AGM, can support the expansion of HSCs, but also suggest that the placental 
microenvironment differs from the fetal liver in that it can maintain an undifferentiated 
state of HSCs. Furthermore, we found that the placental HSC pool, which was maintained 
by E13.5, was reduced drastically to E15.5 and remained very low until E18.5 and birth, 
in contrast to the fetal liver in which HSCs continued to expand. Interestingly, the 
number of circulating HSCs also increased steadily and surpassed the number of HSC in 
placenta at E15.5, showing that the kinetics of HSC activity in the placenta is unique and 
doesn’t merely represent HSCs in fetal circulation. In agreement with other reports 
(Christensen et al., 2004), we observed a major increase of clonogenic progenitors in 
blood around E15.5, while progenitors in the placenta were instead diminishing.  
We next went on to define the immunophenotype of placental HSCs. Adult LT-HSCs 
are found within the lineage-negative (Lin-) c-kithisca-1+ (LSK) compartment, where 
expression of CD34 marks short-term HSCs. However, fetal HSCs express CD34  
indicating a non-quiescent active cycling state (Sanchez et al., 1996). In accordance with 
this, we found that all HSCs and most clonogenic progenitors in the placenta were 
CD34+c-kithi, whereas some progenitors were ckit+-single positive (Figure 4B-D). In 
comparison to the placenta, some fetal liver HSCs and a larger fraction of progenitors 
also resided in the relatively more abundant c-kit+-single positive fraction. Our data have 
been confirmed by others (Ottersbach and Dzierzak, 2005). In that study, a sca-1 
transgenic mouse (Ly6A-GFP) was used to identify the presence of sca-1+ cells in the 
placenta, which in a previous study indicated all HSC activity in the AGM (de Bruijn et 
al., 2002). Although sca-1 expression is not confined solely to hematopoietic lineages in 
the placenta, but is rather widely expressed in endothelial cells and maternal decidua, 
GFP+ cells in placenta were evident as early as E9.5 and increased towards E12.5 
(Ottersbach and Dzierzak, 2005). Co-expression analysis revealed that most GFP+ 
hematopoietic activity was found within the c-kit+CD34+ subset, which is well in line 
with our own results.
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In summary, we identified the placenta as a novel fetal niche for hematopoietic stem 
cells. The placenta displays unique developmental kinetics of definitive HSCs and 
supports the presence of a considerable pool of HSCs during midgestation.  
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8.2. HEMATOPOIETIC STEM CELLS EMERGE IN THE 
PLACENTAL VASCULATURE IN THE ABSENCE OF CIRCULATION 
(II)
The findings presented in Paper I nominate the placenta as an important hematopoietic 
organ, unique in its capacity to sustain a large pool of HSCs while segregating them from 
signals that promote differentiation. However, as discussed above, it was not possible to 
determine whether the placenta is capable of producing HSCs de novo or whether it 
functions solely as a niche for the maturation and expansion of HSCs originating from 
other sites. Defining the origin of HSCs in vivo has been complicated by mainly two 
factors. Firstly, as developing HSCs prior to E10.5 are unable to engraft in lethally 
irradiated adult bone marrow, an assessment of HSC potential through standard in vivo
transplantation assays is not possible, and the culture requirements of emerging HSCs 
remain undefined. Secondly, as blood circulation is initiated already at E8.5, theoretically 
any cell forming in any one site could migrate via the bloodstream to any other site, and 
this has been a major obstacle for developmental studies. In order to address this question 
we utilized the Runx1-LacZ knock-in (North et al., 2002) and Ncx1 knockout (Koushik 
et al., 2001) mouse models to find out whether HSCs are formed in the placenta, and, in 
that case, in what specific niches HSC emergence, maturation and expansion takes place. 
As mentioned earlier, expression of LacZ in Runx1LacZ/+ and Runx1LacZ/LacZ embryos 
was used to visualize sites of definitive hematopoiesis in the placenta. Importantly, since 
Runx1LacZ/LacZ mice have both Runx1 alleles targeted and thus lack expression of Runx1, 
definitive hematopoietic cells never develop. However, cells that would have developed 
into hematopoietic cells and therefore had activated the Runx1 locus can still be 
visualized by LacZ. Thus, we were able to discern between sites of emergence (LacZ-
positive cells (LacZ+) in both Runx1LacZ/+ and Runx1LacZ/LacZ embryos) and sites that 
contain nascent or migrated definitive hematopoietic cells (LacZ+ only in Runx1LacZ/+
embryos). This was confirmed by analysis of sections of AGM, known to generate HSCs 
de novo, and fetal liver which contains blood cells exclusively from other sources. 
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Interestingly, LacZ+ cells where found in the chorioallantoic vessel walls of Runx1LacZ/+ 
placentas (Figure 5B). As Runx1 expression is not restricted to HSCs, the hematopoietic 
identity of these cells was confirmed by co-localization with CD41 which is known to be 
a marker for nascent HSCs and progenitors (Corbel and Salaun, 2002; Mikkola et al., 
2003a). Importantly, similar LacZ+ cells were observed also in Runx1LacZ/LacZ placentas, 
indicating that Runx1-positive cells emerge de novo in the walls of chorioallantoic 
vessels (Figure 5C). In addition, other LacZ+ cell types were found in the chorioallantoic 
mesenchyme of Runx1LacZ/+ and Runx1LacZ/LacZ placentas, such as cuboidal endoderm 
derived cells forming clusters known as Crypts of Duval. Moreover, round LacZ+ cells 
reminiscent of HSCs were found in the lumen of the placental labyrinth only in 
Runx1LacZ/+ but not Runx1LacZ/LacZ placentas (Figures 5D-E). These data nominate the 
chorioallantoic vessels and possibly the chorioallantoic mesenchyme as sites of HSC 
emergence and the labyrinthine vessels as sites of residence, maturation or expansion of 
ready-made HSCs. In addition the data suggest that Runx1+ endodermal structures in 
placenta could play a role in the process of HSC emergence. This notion could be 
supported by the fact that Crypts of Duval express an important signaling molecule, 
Indian hedgehog (Ihh), and surrounding mesenchymal cells its receptor Patched-1 (Ptch1), 
thus forming a functional signaling pathway which in yolk sac and avian allantois is 
important for formation of blood from mesoderm (Baron, 2003). 
Next, to investigate whether the placental microenvironment promotes proliferation 
of hematopoietic cells, we performed co-staining of Runx1LacZ/+ placental sections with a 
mitosis marker (PH3S10). We found that a large proportion of the LacZ+ cells in the 
lumen of the labyrinth vessels were mitotically active whereas only few LacZ+ cells were 
PH3S10+ in the chorioallantoic mesenchyme. This finding suggested that the placental 
labyrinth provides a microenvironment where hematopoietic cells actively proliferate, 
rather than serving as a passive retainer of blood cells. The unique microenvironmental 
characteristics of the labyrinth and its surrounding cell types, including trophoblast cells 
not found anywhere else in the embryo are currently under closer study in our lab. 
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Figure 5. Runx1 Expression Marks the Sites of Definitive Hematopoiesis in the Placenta. (a) 
Schematic of cross-section of placenta. (b-e) Paraffin sections stained with ?-galactosidase (lacZ, blue), 
laminin (mesodermal derivatives, red), and cytokeratin (trophoblast and epithelial cells, brown). (b-c) 
Chorioallantoic vessels of Runx1lacZ/+ and Runx1lacZ/lacZ placentas harbor lacZ+ candidate HSCs (arrow) 
within the vessel walls. Asterisk (*), Crypt of Duval. (d) Labyrinth vessels of the Runx1lacZ/+ placenta 
harbored a number of lacZ+ cells. (e) However, Runx1lacZ/lacZ labyrinth vessels never contained lacZ+ 
cells.
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Finally, we utilized the Ncx1 knockout mouse model in order to answer whether the 
HSCs found in the placenta are generated in situ or are imported via circulation. Ncx1-/- 
embryos have no heartbeat due to a defect in the sodium-calcium exchange pump 1, and 
trafficking of hematopoietic cells via the bloodstream is abolished (Koushik et al., 2001). 
Interestingly CD41+ckit+ cells were found in Ncx1-/- placentas (Figure 6A). Due to the 
Figure 6.  Definitive Hematopoietic Cells Derived from Ncx1-/- Placentas Have Myelo-Erythroid and 
Lymphoid Potential. (A) Definitive hematopoietic progenitors, marked by expression c-kit and CD41 
double positive progenitors were present in Ncx1-/- placentas. (B-D) Placenta, yolk sac, and caudal half of 
the embryos were dissected, and the tissue explants were cultured on OP9 and OP9-DL1 stroma. Myelo-
erythroid (B) and B-lymphoid potential (C) was assessed by FACS after plating of the cells from the OP9 
stroma on methylcellulose culture, whereas T lymphoid potential was assessed directly on OP9-DL1 
stroma (D). (E) Sections of Ncx1-/- placenta stained with CD41 revealing presence of budding 
hematopoietic cells from chorioallantoic vessels. 
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loss of heart function Ncx1-/- embryos do not survive past E10.5, meaning that the 
function of HSCs cannot be studied through in vivo transplantation experiments, as 
described earlier. However, by culturing fetal Ncx1-/- tissue explants in vitro on OP9 and 
OP9-DL1 stroma and methylcellulose cultures, we could show that cells indicative of 
HSCs with the potential to give rise to definitive myelo-erythroid, B-lymphoid and T-
lymphoid progeny were present in Ncx1-/- placenta (Figure 6B-D). Of note, similar to the 
aorta where hemogenic clusters expressing Runx1 are observed (North et al., 1999), 
clusters of round hematopoietic cells expressing CD41 were observed in the chorio-
allantoic vasculature of E10.5 Ncx-/- placenta (Figure 6E). Thus, our study suggests that 
in addition to the AGM and the yolk sac, the placenta is capable of de novo generation of 
HSCs (Rhodes et al., 2008). 
Figure 7.  Revised model of fetal HSC development. Fetal hematopoiesis can be divided into at least 
three different waves. The first waves of hematopoiesis occur in the yolk sac: the primitive wave, which 
gives rise to primitive erythroblasts, and the transient definitive wave, which generates myelo-erythroid 
progenitors that first colonize the liver. In contrast, the emergence of adult repopulating HSCs occurs in 
multiple sites yet is confined to the major blood vessels: the dorsal aorta, the adjacent vitelline, umbilical 
vessels, and as shown in this study, the large vessels of the placenta. Subsequently, HSCs generated in the 
placenta and possibly the AGM and yolk sac are directed via blood flow to the placental labyrinth, which 
may provide a unique environment for HSC expansion/maturation prior to seeding of the fetal liver. Pink 
marks mesodermal tissues with hematopoietic potential (al, allantois; ch, chorion; ys, yolk sac; and p-sp, 
para-aortic splanchopleura) and their derivatives (ua, umbilical artery; cv, chorio-allantoic vessels; va, 
vitelline artery; and da, dorsal aorta), and brown marks trophoectodermal tissues (epc, ectoplacental cone 
and lb, placental labyrinth). Dec, maternal decidua and fl, fetal liver. 
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In summary we have identified in Papers I and II an important, previously unknown site 
for HSC development, and therefore the current model of fetal HSC development needs 
to be revised (see Figure 7). We propose that the placenta is required for the de novo 
generation and initial expansion of an undifferentiated HSC pool. The placental HSC 
pool is transient, as HSCs in the placenta diminish in numbers probably due to migration 
to the fetal liver and other sites, such as the fetal bone marrow. In contrast to the fetal 
liver, the placenta HSC niche does not serve as a site for myeloerythroid or lymphoid 
differentiation. As such, it would be of great general interest to further characterize the 
stem-cell promoting properties of the placenta microenvironment. It is worth mentioning 
that ongoing work in our laboratory has led to the establishment of stroma cell lines from 
human first trimester placenta that support the remarkable expansion of human 
CD34+CD38-CD90+ cells (i.e. the most immature HSC phenotype in human) ex vivo.
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8.3. SCL/TAL1 IS REQUIRED ONLY TRANSIENTLY FOR 
HEMATOPOIETIC SPECIFICATION (III)
As described above, the stem cell-leukemia gene (Scl/Tal1) is essential for the initiation 
of hematopoiesis and loss of Scl leads to total lack of all blood lineages in the embryo 
(Shivdasani et al., 1995). As Scl is and remains expressed in fetal and adult HSCs it was 
postulated that the continuous presence of Scl was required to maintain stem cell function 
in HSCs. However, the inducible deactivation of Scl in the adult did not lead to loss of 
HSC numbers or defects in HSC engraftment and long-term repopulating ability upon 
transplantation to irradiated hosts (Mikkola et al., 2003b). On the other hand, erythroid 
and megakaryocyte progenitors in the bone marrow and platelets in the blood were 
severely affected (Hall et al., 2003; Mikkola et al., 2003b). Thus, these findings showed 
that Scl is dispensable for HSC maintenance but remains critical for erythroid and 
megakaryocyte development in the adult BM, yet did not reveal at what stage HSC 
development becomes Scl-independent. 
In order to better understand the roles of Scl in the establishment of the hematopoietic 
system, we sought to define the temporal window of Scl requirement during fetal HSC 
development. To address this question, we crossed a conditionally targeted Sclfl/fl mouse 
strain with a Tie2-Cre mouse strain (Kisanuki et al., 2001; Mikkola et al., 2003b). Tie2 
(Tyrosine kinase with immunoglobulin and epidermal growth factor homology domains–
2) is the receptor for angiopoietin 1 (Ang1), an important signaling factor for 
vasculogenesis. As such, expression of Tie2 marks endothelial cells in hemogenic and 
vasculogenic sites in the embryo, and has been shown to be expressed on HSCs (Hsu et 
al., 2000; Schlaeger et al., 1997).  Upon crossing of the Sclfl/fl and Tie2-Cre mouse strains, 
expression of Cre recombinase is driven by the Tie-promoter and leads to excision and 
deactivation of the conditionally targeted Scl locus in endothelial and hematopoietic stem 
cells.
We could show that expression of Scl was completely abolished in hematopoietic 
cells of the fetal liver by embryonic day E12.5. In contrast to Scl-/- embryos that die 
before E9.5 due to absence of blood cells and disrupted vasculature, Sclfl/fl x Tie2Cre 
embryos survived until E13.5-14.5 and had circulating primitive erythrocytes. However, 
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morphological and FACS analysis of the cellular composition of E12.5-13.5 peripheral 
blood and fetal liver exposed a maturation defect of primitive erythroid cells at the level 
of CD71+ter119+ basophilic erythroblasts (Figure 8A). Furthermore, acetylcholine-
esterase (AchE) staining of E12.5 fetal liver cultures revealed a severe reduction of 
mature megakaryocytes (Figure 8B). Therefore, as in the adult, we concluded that Scl is 
critically required for fetal erythroid and megakaryocyte development.  
Figure 8. Effect of Tie2Cre-mediated deletion of Scl gene in the development and function of 
primitive and definitive hematopoietic cells. (A) FACS analysis of CD71 and ter119 expression on 
primitive erythrocytes from E12.5 fetal liver (FL). (B) Acetylcholine-esterase staining of E12.5 FL. (C) 
Total cellularity and colony-forming cells (CFCs) in E12.5 fetal liver. (D) FACS analysis of c-kit and sca-1 
expression on definitive progenitor populations in fetal liver. (E) Short- and long term analysis of 
competitive repopulation after transplantation of fetal liver derived HSCs into adult hosts. (F) Model of Scl 
requirement during hematopoiesis. Scl is essential for specification of hematopoiesis but not for HSC 
emergence, maturation, expansion or self-renewal. However, during fetal and adult hematopoiesis, Scl is 
critical for proper megakaryocyte and erythroid development.  
- 43 -
Hematopoietic Stem Cell Development and Transcriptional Regulation 
To investigate whether early loss of Scl affected the formation and function of 
definitive hematopoietic progenitors, we assessed the colony-forming unit (CFU) 
capacity of fetal liver on methylcellulose culture assays. Of note, the number of colony-
forming progenitors in Tie2Cre+Sclfl/fl fetal liver as well as the total feta liver cellularity 
were only slightly reduced (Figure 8C). Furthermore, FACS analysis of known 
progenitor and stem cell markers revealed the presence of c-kit+sca-1+ and ckit+sca1- cells, 
indicating that definitive progenitors form and display no proliferation or maturation 
defects in the absence of Scl (Figure 8D). Finally, to assess whether also functional adult-
type HSCs were present, fetal liver cells were transplanted into irradiated adult hosts. 
Importantly, we found that Tie2Cre+Sclfl/fl cells were capable of short (3-4 wks) and long-
term (>5 months) reconstitution of the recipient blood system arguing that ongoing 
expression of Scl is not required for function of fetal liver LT-HSCs (Figure 8E).
Our data thus suggest that the developmental time window during which cells require 
Scl in order to establish the hematopoietic program is prior to and overlapping with the 
onset of Tie2 expression. Importantly, in contrast to its transient requirement in 
hematopoietic specification, Scl remains essential for proper development of erythroid 
and megakaryocytic cells throughout embryonic, fetal, and adult hematopoiesis (Figure 
8F). In summary these findings highlight that, once specified, the hematopoietic fate is 
stable and is maintained through yet undefined mechanisms that are distinct from those 
required for the initial fate choice.
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8.4. MEF2C IS A LINEAGE-RESTRICTED TARGET OF SCL/TAL1
AND REGULATES MEGAKARYOPOIESIS AND B-CELL
HOMEOSTASIS. (IV)
As shown by our previous study (Paper III), in spite of the pivotal role of Scl in the 
initiation of the blood program, Scl becomes dispensable for further development and 
function of HSCs shortly after hematopoietic specification (Schlaeger et al., 2005). 
Although the entire hematopoietic transcriptional program can be regarded as being 
downstream of Scl, the direct target genes of Scl during hematopoietic specification and 
differentiation are not known. Neither has it been defined whether Scl regulates shared or 
unique gene expression programs depending on its cellular context. Our results suggest 
that Scl utilizes different mechanisms for regulating at least a subset of target genes 
during hematopoietic specification vs. lineage differentiation (Schlaeger 2005, Mikkola 
2003).
To understand how the same transcription factor regulates different developmental 
fates within the hematopoietic hierarchy, we sought to identify Scl target genes in the 
different cell types. We thus generated hematopoietic progenitor cell lines from E12.5 
Sclfl/fl fetal liver cells by immortalization with Hox11 retrovirus (Keller et al., 1998). The 
cell lines were cultured in the presence of IL-3 and selected for megakaryocyte specific 
activity of acetylcholine esterase (AchE). Scl expression was then abolished (Scl?/? cell 
line) and subsequently rescued (Scl?/?/+Scl cell line) through transduction with Cre-GFP 
and Scl retroviruses, respectively, thus establishing serial cell lines. Importantly, the 
Scl?/? cell line exhibited an arrest in megakaryocyte differentiation as demonstrated by 
loss of AchE+ cells, whereas AchE-activity was rescued in the Scl?/?/+Scl cell line, 
confirming that the cell lines remained responsive to megakaryocytic induction in the 
presence of Scl. The differential gene expression between the three cell lines was 
analyzed by Affymetrix microarray after culture with IL3 and TPO for 5 days and 
enabled identification of Scl-dependent genes in the megakaryocytic lineage.   
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Among the top downregulated genes in the absence of Scl were known 
megakaryocytic, erythroid or other hematopoietic or vascular cell genes, as well as 
miscellaneous genes and as yet unknown ESTs/cDNAs not previously linked to blood 
development. One of the top downregulated genes was the transcription factor Mef2C. 
Importantly, we could show by ChIP-on-chip analysis on the megakaryocytic cell line 
L8057 that Scl binds to the Mef2C promoter directly. Moreover, binding of Scl was 
associated with acetylation of histone 3 lysine 9 (H3K9Ac), which as mentioned earlier is 
an indicator of gene activation. Importantly, in erythroid cells, where Mef2C is not 
expressed, no significant levels of Scl binding or H3K9Ac were observed on the 
promoter of Mef2C. This suggests that Scl uses distinct target genes in different cell 
types to regulate differentiation. Thus, we conclude that Mef2C is a novel direct target 
gene of Scl in megakaryocytes.  
Mef2C (myocyte enhancer factor 2 C) is a member of the MADS-box transcription 
factor family, which were originally discovered as important regulators of skeletal, 
smooth and cardiac muscle development (Black and Olson, 1998; Lin et al., 1998). 
Homozygous deletion of Mef2C was reported to result in cardiac and vascular defects 
that together lead to early embryonic lethality at E9.5 (Black and Olson, 1998; Lin et al., 
1998). Until recently, a role of Mef2C in hematopoiesis was unknown; however, 
implications of Mef2C in various types of leukemias, and expression of Mef2C in 
hematopoietic populations suggested a role of Mef2C also during physiological 
hematopoietic processes (Fuhrken et al., 2008; Krivtsov et al., 2006).
We therefore sought to investigate a role of Mef2C in hematopoiesis. First, we found 
that Mef2C is downstream of Scl also during embryonic development, through Q-PCR 
analysis of Mef2C mRNA expression in fetal hematopoietic and vascular tissues of E9.0 
Scl-/- embryos. Mef2C expression was reduced in the yolk sac and caudal half of the 
embryo which contains the para-aortic splanchnopleura (p-Sp), a site of hematopoietic 
stem cell emergence and somite development (Cumano et al., 2001; Godin et al., 1995). 
On the other hand, expression of Mef2C in the heart was unaltered compared to controls. 
Taken together, these data imply that Mef2C is either directly regulated by Scl within the 
same cell, or that cells in which Mef2C would be expressed are reduced by loss of Scl.
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However, loss of Mef2C in conventional knockout Mef2C-/- embryos did not 
recapitulate the profound hematopoietic defects observed in Scl-/- embryos, namely total 
loss of blood cells (Shivdasani et al., 1995; Visvader et al., 1998). Interestingly, although 
the yolk sac vasculature appeared perturbed, the yolk sacs of Mef2C-/- embryos contained 
pools of blood (Figure 9A), suggesting that Mef2C is not essential for primitive 
erythropoiesis, which was confirmed by FACS analysis of yolk sac for presence of 
CD71+ and ter119+ erythroblasts.
To assess a role of Mef2C in establishing definitive hematopoiesis we analyzed the in 
vitro hematopoietic potential of fetal hematopoietic tissues of Mef2C-/- E8.5-9.5 embryos. 
Multi-lineage definitive clonogenic were present at levels comparable to controls in the 
placenta and yolk sac of Mef2C-/- embryos, whereas only very rare functional 
hematopoietic progenitors were found in the caudal half of Mef2C-/- embryos. In order to 
assess whether the poor capacity to generate hematopoietic progenitors in Mef2C-/-
embryo proper was due to a cell intrinsic requirement for Mef2C in hematopoietic cells in 
the embryo proper, cell suspensions were initially co-cultured on a supportive OP9-
stroma before being transferred to methylcellulose, as shown in Paper II (Rhodes et al., 
2008). Interestingly, the ability to generate hematopoietic progenitors in the caudal half 
of the Mef2C-/- embryos was partially rescued after 4 days of OP9 co-culture, indicating 
that there is no cell-autonomous block in specification of definitive progenitors in the 
embryo proper. Importantly, all organs displayed B-lymphoid hematopoietic potential 
after culture on OP9 stroma, as assessed by FACS.  
Thus, we could conclude that in contrast to Scl, Mef2C is not absolutely required for 
hematopoietic specification and emergence of primitive and definitive hematopoietic 
progenitors. As Mef2C-/- mice die in utero, analysis of a potential role of Mef2C in post-
natal life using this model was precluded. In order to study the potential requirement of 
Mef2C in adult hematopoiesis, we utilized a conditionally targeted Mef2Cfl/fl mouse 
strain, which we crossed with a VavCre mouse strain (Arnold et al., 2007; Stadtfeld and 
Graf, 2005). As the Vav promoter drives Cre recombinase expression exclusively in 
hematopoietic lineages shortly after the emergence of HSCs, Mef2C was specifically 
targeted for deletion in all fetal and adult hematopoietic lineages.  
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A
B
C
Figure 9. Mef2C is not critical for fetal hematopoiesis, but in the adult Mef2C is important for 
platelet development and B cell homeostasis. (A) Pictures of wild-type, Scl-/- and Mef2C-/- embryos, 
showing the presence of blood in Mef2C-/- yolk sac. (B) Complete blood cytometry (CBC) analysis of 
peripheral blood showed that VavCre+Mef2Cfl/fl mice exhibit marked thrombocytopenia and increased 
platelet size. Circles indicate analysis of individual mice. (PLT; platelet count, MPV; mean platelet 
volume) (*** indicates p<0.0005). Electron microscopy imaging of platelets reveals severe ultrastructural 
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Figure 9. Continued: defects of Mef2C-deficient platelets, including enlarged size and loss of elongated 
form. In addition, Mef2C deficient platelets demonstrated a loss of ?-granules (solid arrows) and an 
increase in depleted granules (dashed arrows). (C) FACS analyses of frequencies of B cell subsets in bone 
marrow of VavCre+Mef2Cfl/fl and age-matched littermate control mice, for expression of B220, IgM, CD43 
and CD24. Panels i-ii display representative examples of young (1 month) and older (15 month) mice, 
respectively. Frequency of B220+IgM+ B cells was not significantly altered regardless of age. Subgating on 
IgM- cells visualizes pre-B and pro-B populations. Strikingly, older, but not young, mice exhibited severe 
reductions of pre-B cells. Subgating on B220+CD43+ cells visualizes pre-pro-B (Fr. A) and pro-B cells (Fr. 
B-C). Of note, a slight reduction in the frequency of pre-pro-B cells was noted in both young and older 
mice.
Of note, VavCre+Mef2Cfl/fl survived into adulthood demonstrating that loss of Mef2C 
during fetal hematopoiesis or adult steady state hematopoiesis does not result in profound 
hematopoietic failure. Also most peripheral blood parameters were unperturbed, as 
analyzed by complete blood cytometry (CBC). However, we found that 
VavCre+Mef2Cfl/fl mice, as Scl-deficient mice, displayed thrombocytopenia and enlarged 
platelet size (Figure 9B). Moreover, electron microscopy of Mef2C-deficient platelets 
revealed ultrastructural defects, including loss of elongated forms and reduction in 
platelet granularity (Figure 9B), highly similar to Scl-deficient platelets (McCormack et 
al., 2006).
To understand the requirement of Mef2C for megakaryocyte development we next 
turned to the bone marrow to assess the state of ongoing megakaryopoiesis. We could 
conclude that frequencies of MEPs and single-lineage megakaryocyte committed 
progenitors (CFU-Mk) were increased in VavCre+Mef2Cfl/fl BM. Interestingly, mature 
megakaryocytes as defined by acetylcholinesterase staining (AchE+), DNA content, and 
high expression of CD41 and CD31 megakaryocytes were present despite loss of Mef2C. 
These data suggest that the reduction in platelet count due to absence of Mef2C is not 
caused by decreased commitment to the megakaryocyte lineage or initial maturation of 
megakaryocytes, but rather due to defects in platelet formation. Interestingly, when 
Mef2C deficient BM was cultured in vitro in megakaryopoietic conditions, we observed a 
severe reduction in formation of AchE+ cells from VavCre+Mef2Cfl/fl BM. This 
phenotype is highly reminiscent to the megakaryocyte defect observed in cultures of Scl-
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deficient bone marrow, where no AchE+ megakaryocytes could be observed. These data 
clearly document a cell autonomous requirement of Mef2C for proper 
megakaryocyte/platelet development, and nominate the Scl-Mef2C axis as an important 
regulatory entity utilized specifically in the megakaryocyte lineage. 
In addition to the defects in the platelet compartment, we observed reductions in 
peripheral blood B220+IgM+ B-cells, which were not correlated with a decrease in mature 
IgM+ B cells in the spleen. Analysis of BM of both young and older VavCre+Mef2Cfl/fl
mice revealed a reduction in the frequency of pre-pro-B cells (Figure 9C). Strikingly, 
older VavCre+Mef2Cfl/fl mice exhibited a severe reduction of the pre-B cell compartment, 
in stark contrast to their age-matched littermate controls (Figure 9C). Even so, the 
frequency of mature IgM+ B-cells was not altered compared to age-matched controls, 
regardless of age. This phenotype is very similar to the defects associated with B-cell 
aging (reviewed in (Riley et al., 2005)), Taken together, these data indicate a previously 
unappreciated role for Mef2C in bone marrow B-cell homeostasis. 
In summary, our data demonstrate that within the adult hematopoietic system Mef2C, 
as Scl, is required for proper platelet development (Figure 10). In addition, our data 
indicate an Scl-independent requirement of Mef2C in B-cell homeostasis (Figure 10). As 
Scl is not expressed in B-cells, Mef2C expression in B-cells is regulated proposedly by 
other bHLH factors, such as E12/E47 known to be implicated in B-cell aging. 
Furthermore, Scl’s role in hematological malignancies and Mef2C’s recent implication as 
a cooperating oncogene in leukemia (Du et al., 2005; Krivtsov et al., 2006; Nagel et al., 
2007; Suzuki et al., 2002) raises the interesting hypothesis that Mef2C may be regulated 
by Scl or other bHLH factors also during leukemogenesis. However, the fact that Scl was 
unable to bind and activate the Mef2C promoter in erythroid cells suggests that additional 
prerequisites have to be fulfilled to activate Mef2C expression.  Therefore, unraveling the 
mechanisms by which Mef2C expression is regulated, and how Mef2C subsequently 
controls cell proliferation and survival in different tissues may shed light not only on 
these physiological developmental processes but also on the pathogenesis of malignant 
blood diseases. 
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Figure 10. Model of Mef2C gene regulation in the hematopoietic hierarchy. Unlike Scl, which is 
absolutely required for the specification of mesoderm to blood and emergence of HSCs, Mef2C is not 
critically involved in embryonic hematopoiesis. Mef2C is however required for skeletal muscle and cardiac 
lineage differentiation. In the adult, we discovered novel requirements for Mef2C in two hematopoietic 
lineages. In B cells, where Scl is not expressed, Mef2C likely acts downstream of other bHLH factors (e.g. 
E12/E47) to counteract B lymphocyte aging, especially within the pre-B cell fraction. Our data indicate that 
in the megakaryocytic lineage, that Mef2C is a direct target gene of Scl and, as Scl, is required for proper 
megakaryopoiesis and platelet biogenesis. Although Scl is required for erythroid differentiation, Scl is not 
bound to the Mef2C promoter in erythroid cells. Finally, Mef2C was recently shown to be expressed in 
myeloid cells where it acts to modulate myeloid cell fates (Schuler et al., 2008). Bold text in red indicates 
expression and functional requirement, grey text indicates expression but no functional requirement in the 
specific lineages. HSC; hematopoietic stem cell, MPP; multipotent progenitor, CLP; common lymphoid 
progenitor; CMP, common myeloid progenitor, Meg; megakaryocyte, Ery; erythroid progenitor. 
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